Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI0002h CAR T cells versus standard of care for relapsed/refractory multiple myeloma
NL-OMON61089Phase 3Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing ARI0002h CAR T-cell arm with Standard-of-care arm (2 arms). Primary endpoint: Progression-free survival. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ARI0002h
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON61089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61089.